Cognitive dysfunction: An emerging concept of a new diabetic complication in the elderly

Geriatrics and Gerontology International

Volumn 13, Issue 1, 2013, Pages 28-34

  Umegaki, Hiroyuki ^a   Hayashi, Toshio ^a   Nomura, Hideki ^a,b   Yanagawa, Madoka ^a   Nonogaki, Zen ^a   Nakshima, Hirotaka ^a   Kuzuya, Masafumi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Ajima Clinic   (Japan)

Author keywords

Alzheimer's disease type dementia; Hypoglycemia; Insulin resistance; Neurocognitive assessment; Vascular dementia

Indexed keywords

ACETYLCHOLINE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; INSULIN; OLANZAPINE; QUETIAPINE;

AGED; AGING; ATTENTION; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOM OF DEMENTIA; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DRUG EFFICACY; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; MINI MENTAL STATE EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

AGED; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; EXERCISE THERAPY; HUMANS; HYPOGLYCEMIC AGENTS; NEUROPSYCHOLOGICAL TESTS;

EID: 84871969895     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2012.00922.x     Document Type: Review

References (79)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Abi Khalil C, Roussel R, Mohammedi K, Danchin N, Marre M. Cause-specific mortality in diabetes: recent changes in trend mortality. Eur J Cardiovasc Prev Rehabil 2012; 19: 374-381.
3. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999; 58: 1937-1941.
4. Ohara T, Doi Y, Ninomiya T etal. Glucose tolerance status and risk of dementia in the community: the Hisayama study. Neurology 2011; 77: 1126-1134.
5. Matsuzaki T, Sasaki K, Tanizaki Y etal. Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 2010; 75: 764-770.
6. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Benette DA. Diabetes mellitus and risk of Alzheimer's disease and decline in cognitive function. Arch Neurol 2004; 61: 661-666.
7. Peila R, Rodriguez BL, Launer LJ. Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies. Diabetes 2002; 51: 1256-1262.
8. Peila R, Rodriguez BL, White LR, Launer LJ. Fasting insulin and incident dementia in an elderly population of Japanese-American men. Neurology 2004; 63: 228-233.
9. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes - systematic overview of prospective observational studies. Diabetologia 2005; 48: 2460-2469.
10. Kopf D, Frölich L. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis 2009; 16: 677-685.
11. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.
12. Daviglus ML, Plassman BL, Pirzada A etal. Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol 2011; 68: 1185-1190.
13. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10: 819-828.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method of grading the cognitive function of patients or the clinician. J Psychiatr Res 1978; 12: 189-198.
15. Sakurai T, Kuranaga M, Akisaki T, Takata T, Endo H, Yokono K. Differential mini-mental state examination profiles of older people with diabetes mellitus with early Alzheimer's disease. J Am Geriatr Soc 2007; 55: 955-956.
16. Fillenbaum GG, Wilkinson WE, Welsh KA, Mohs RC. Discrimination between stages of Alzheimer's disease with subsets of Mini-Mental State Examination items. An analysis of Consortium to Establish a Registry for Alzheimer's Disease data. Arch Neurol 1994; 51: 916-921.
17. van den Berg E, Kloppenborg RP, Kessels RP, Kappelle LJ, Biessels GJ. Type 2 diabetes mellitus, hypertension, dyslipidemia and obesity: a systematic comparison of their impact on cognition. Biochim Biophys Acta 2009; 1792: 470-481.
18. Umegaki H, Kawamura T, Mogi N, Umemura T, Kanai A, Sano T. Glucose control levels, ischaemic brain lesions, and hyperinsulinaemia were associated with cognitive dysfunction in diabetic elderly. Age Ageing 2008; 37: 458-461.
19. Umegaki H, Kawamura T, Kawano N, Umemura T, Kanai A, Sano T. Factors associated with cognitive declines in elderly diabetics. Dement Geriatr Cogn Disord Extra 2011; 1: 1-9.
20. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Association, 1985.
21. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010; 120: 287-296.
22. Yamagishi S, Ueda S, Okuda S. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders. Curr Pharm Des 2007; 13: 2832-2836.
23. Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 2010; 37: 67-76.
24. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69.
25. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003; 17: 27-45.
26. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Gilman AG, Limbird LE, eds. Gilman and Goodman's the Pharmacological Basis of Therapeutics, 9th edn. New York: McGraw-Hill, 1996; 1487-1517.
27. Woods SC, Seeley RJ, Baskin DG, Schwartz MW. Insulin and the blood-brain barrier (BBB). Curr Pharm Des 2003; 9: 795-800.
28. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978; 272: 827-829.
29. Freychet P. Insulin receptors and insulin action in the nervous system. Diabetes Metab Res Rev 2000; 16: 390-392.
30. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis 2005; 8: 247-268.
31. De Felice FG, Vieira MN, Bomfim TR etal. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci USA 2009; 106: 1971-1976.
32. Lacor PN, Buniel MC, Chang L etal. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004; 24: 10191-10200.
33. Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 2009; 1792: 482-496.
34. Craft S, Peskind E, Schwartz MW, Schellenberg GD, Raskind M, Porte D Jr. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998; 50: 164-168.
35. Craft S, Baker LD, Montine TJ etal. Intranasal insulin therapy for Alzheimer disease and Amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012; 69: 29-38.
36. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127: 481-496.
37. Benedict C, Hallschmid M, Hatke A etal. Intranasal insulin reportedly improves memory and attention in humans. Psychoneuroendocrinology 2004; 29: 1326-1334.
38. Li L, Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007; 56: 384-402.
39. Takeda S, Sato N, Rakugi H, Morishita R. Molecular mechanisms linking diabetes mellitus and Alzheimer disease: β-amyloid peptide, insulin signaling, and neuronal function. Mol Biosyst 2011; 7: 1822-1827.
40. Beeri MS, Silverman JM, Davis KL etal. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 2005; 60: 471-475.
41. Arvanitakis Z, Schneider JA, Wilson RS etal. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006; 7: 960-1965.
42. Manschot SM, Biessels GJ, de Valk H etal. Metabolic and vascular determinants of impaired cognitive performance and abnormalities on brain magnetic resonance imaging in patients with type 2 diabetes. Diabetologia 2007; 50: 2388-2397.
43. Araki A, Ito H. Asymptomatic cerebral infarction on brain MR images and cognitive function in elderly diabetic patients. Geriatr Gerontol Int 2002; 2: 206-214.
44. Akisaki T, Sakurai T, Takata T etal. Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus. Japanese elderly diabetes intervention trial (J-EDIT). Diabetes Metab Res Rev 2006; 22: 376-384.
45. Mogi M, Horiuchi M. Neurovascular coupling in cognitive impairment associated with diabetes mellitus. Circ J 2011; 75: 1042-1048.
46. Lok J, Gupta P, Guo S etal. Cell-cell signaling in the neurovascular unit. Neurochem Res 2007; 32: 2032-2045.
47. Li J, Wang YJ, Zhang M etal. Chongqing Ageing Study Group. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011; 76: 1485-1491.
48. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009; 73: 674-680.
49. Gao L, Matthews FE, Sargeant LA etal. An investigation of the population impact of variation in HbA1c levels in older people in England and Wales: from a population based multi-centre longitudinal study. BMC Public Health 2008; 8: 54;doi: 10.1186/1471-2458-8-54.
50. Maggi S, Limongi F, Noale M etal. LSA Study Group. Diabetes as a risk factor for cognitive decline in older patients. Dement Geriatr Cogn Disord 2009; 27: 24-33.
51. Christman AL, Matsushita K, Gottesman RF etal. Glycated haemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study. AR, Selvin E. Diabetologia 2011; 54: 1645-1652.
52. Cukierman-Yaffe T, Gerstein HC, Williamson JD etal. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial; Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes(ACCORD-MIND)Investigators. Diabetes Care 2009; 32: 221-226.
53. Launer LJ, Miller ME, Williamson JD etal. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 2011; 10: 969-977.
54. Gradman TJ, Laws A, Thompson LW, Reaven GM. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 1993; 41: 1305-1312.
55. Meneilly GS, Cheung E, Tessier D, Yakura C, Tuokko H. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 1993; 48: M117-M121.
56. Naor M, Steingruber HJ, Westhoff K, Schottenfeld-Naor Y, Gries AF. Cognitive function in elderly non-insulin-dependent diabetic patients before and after inpatient treatment for metabolic control. J Diabetes Complications 1997; 11: 40-46.
57. Hewer W, Mussell M, Rist F, Kulzer B, Bergis K. Short-term effects of improved glycemic control on cognitive function in patients with type 2 diabetes. Gerontology 2003; 49: 86-92.
58. Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MW. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 2006; 29: 345-351.
59. Abbatecola AM, Rizzo MR, Barbieri M etal. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67: 235-240.
60. Mussell M, Hewer W, Kulzer B, Bergis K, Rist F. Effects of improved glycae Large prospective study are warranted regarding this issue. Diabet Med 2004; 21: 1253-1256.
61. Di Filippo C, Verza M, Coppola L, Rossi F, D'Amico M, Marfella R. Insulin resistance and postprandial hyperglycemia the bad companions in natural history of diabetes: effects on health of vascular tree. Curr Diabetes Rev 2007; 3: 268-273.
62. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301: 1565-1572.
63. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011; 32: 1626-1633.
64. Mossello E, Ballini E, Boncinelli M etal. Glucagon-like peptide-1, diabetes, and cognitive decline: possible pathophysiological links and therapeutic opportunities. Exp Diabetes Res 2011; 31: Article ID 281674;doi: 10.1155/2011/281674.
65. McClean PL, Parthsarathy V, Faivre E, Hölscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 2011; 31: 6587-6594.
66. Angevaren M, Aufdemkampe G, Verhaar HJ, Aleman A, Vanhees L. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment. Cochrane Database Syst Rev 2008; (16): CD005381.
67. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 2009; 39: 3-11.
68. Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004; 85: 1694-1704.
69. Sinclair AJ, Girling AJ, Bayer AJ. Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self-management and use of care services. All Wales Research into Elderly (AWARE) Study. Diabetes Res Clin Pract 2000; 50: 203-212.
70. Araki A, Nakano T, Oba K etal. Low well-being, cognitive impairment and visual impairment associated with functional disabilities in elderly Japanese patients with diabetes mellitus. Geriatr Gerontol Int 2004; 4: 27-36.
71. McGuire LC, Ford ES, Ajani UA. The impact of cognitive functioning on mortality and the development of functional disability in older adults with diabetes: the second longitudinal study on aging. BMC Geriatr 2006; 6: 8; doi: 10/1186/1471-2318-6-8.
72. Panza F, Frisardi V, Capurso C etal. Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am J Geriatr Psychiatry 2010; 18: 98-116.
73. Iwata I, Munshi MN. Cognitive and psychosocial aspects of caring for elderly patients with diabetes. Curr Diab Rep 2009; 9: 140-146.
74. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000; 23: 934-942.
75. Dotson VM, Resnick SM, Zonderman AB. Differential association of concurrent, baseline, and average depressive symptoms with cognitive decline in older adults. Am J Geriatr Psychiatry 2008; 16: 318-330.
76. Ganguli M, Du Y, Dodge HH, Chang CC. Depressive symptoms and cognitive decline in late life: a prospective epidemiological study. Arch Gen Psychiatry 2006; 63: 153-160.
77. Lustman PJ, Clouse RE. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications 2005; 19: 113-122.
78. Feil DG, Lukman R, Simon B, Walston A, Vickrey B. Impact of Dementia on Caring for Patients' Diabetes. Sepulveda, CA: Health Services Research and Development Center of Excellence, Veterans Affairs Greater Los Angeles Healthcare System, 2011.
79. Zheng L, Mack WJ, Dagerman KS, Hsiao JK, Lebowitz BD, Lyketsos CG. Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. Am J Psychiatry 2009; 166: 583-590.